drugset / Trial / NCT06052423
ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2,open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with small cell lung cancer(SCLC).
Timeline
- Start
- 2024-11-30
- Primary completion
- 2025-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20093 | Other / unclassified | 10 mg/kg | Intravenous |